[{"id":"3fa8b4e4-5808-4ba8-b524-7db4cfb6614d","acronym":"MAHOGANY","url":"https://clinicaltrials.gov/study/NCT04082364","created_at":"2021-01-17T17:54:33.576Z","updated_at":"2024-07-02T16:35:03.564Z","phase":"Phase 2/3","brief_title":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","source_id_and_acronym":"NCT04082364 - MAHOGANY","lead_sponsor":"MacroGenics","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Margenza (margetuximab-cmkb) • Zynyz (retifanlimab-dlwr) • tebotelimab (MGD013)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 09/30/2019","start_date":" 09/30/2019","primary_txt":" Primary completion: 01/15/2024","primary_completion_date":" 01/15/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-05-15"},{"id":"db068b7e-0c84-41a8-8c88-e6838f8d4682","acronym":"","url":"https://clinicaltrials.gov/study/NCT03219268","created_at":"2021-01-17T17:21:23.536Z","updated_at":"2024-07-02T16:35:25.591Z","phase":"Phase 1","brief_title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","source_id_and_acronym":"NCT03219268","lead_sponsor":"MacroGenics","biomarkers":" PD-L1 • PD-1 • LAG3","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • LAG3 expression • MHC-II expression","tags":["PD-L1 • PD-1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • LAG3 expression • MHC-II expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Margenza (margetuximab-cmkb) • tebotelimab (MGD013)"],"overall_status":"Completed","enrollment":" Enrollment 277","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 02/08/2023","primary_completion_date":" 02/08/2023","study_txt":" Completion: 02/08/2023","study_completion_date":" 02/08/2023","last_update_posted":"2023-12-21"},{"id":"7aab657d-ec00-44a4-a26a-a330dd1b6981","acronym":"","url":"https://clinicaltrials.gov/study/NCT04129320","created_at":"2021-01-18T20:10:22.793Z","updated_at":"2024-07-02T16:36:17.436Z","phase":"Phase 2/3","brief_title":"Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT04129320","lead_sponsor":"MacroGenics","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • tebotelimab (MGD013) • enoblituzumab (MGA271)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-02-08"}]